European Patent Office rejects 3M aerosol claims:
This article was originally published in Clinica
The European Patent Office has rejected claims from 3M subsidiary, Riker Labs, relating to the use of hydrofluoroalkane (HFA) as a propellant in asthma drug delivery devices. According to Miami, Florida-based IVAX, the patent was rejected for lack of novelty and it also removes an obstacle to the marketing of such devices by IVAX itself. Its subsidiary, UK-based Norton Healthcare, has already received approvals in France and Ireland for the use of the HFA propellant with beclomethasone.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.